Beta‐Lapachone: Effects on Proliferation, Survival, Migration, Cell Cycle, and lncRNA Modulation in Bladder Cancer Cells With Distinct TP53 Profiles
Drug Development Research · 2025
DOI: 10.1002/ddr.70128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Tatiane Roquete Amparo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Ouro Preto, Ouro Preto, Brazil. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, RNA, Long Noncoding, Naphthoquinones, Tumor Suppressor Protein p53. Die Arbeit nennt 57 Literaturangaben.
Abstract (Originalsprache)
α‐Lapachone (aLAP) and β‐lapachone (bLAP) are noteworthy anticancer naphthoquinones. The chemoresistance observed in bladder cancer represents a global health concern, with relation to mutations in the TP53 gene and alterations in the expression of long noncoding RNA (lncRNAs). This study evaluated the effects of aLAP and bLAP on bladder tumor cell lines with different TP53 statuses: RT4 low‐grade tumor with wild‐type TP53 ), T24 and J82 (high‐grade tumor with mutation in the TP53 gene). Cytotoxicity was assessed using the MTT reduction method and cell migration by scratch assay, while clonogenic survival and cell cycle were evaluated through cell colony counting and flow cytometry, respectively. The expression of lncRNAs linked to bladder cancer and associated with tumor progression and prognosis ( JHDM1D‐AS1 , SBF2‐AS1 , CDT‐2132N18.2 , and RP11‐363E7.4 ) and the JHDM1D gene was evaluated through RT‐qPCR. bLAP demonstrated greater cytotoxicity than aLAP. Its inhibitory effects on clonogenic survival, migration, and the cell cycle were observed in all cell lines and were related to the modulation of lncRNAs expression. A reduction in lncRNA SBF2‐AS1 and JHDM1D gene expression was observed in RT4 cells, accompanied by an increase in lncRNA RP11‐363E7.4 . Conversely, in the cells with mutated TP53 (J82), a reduction in JHDM1D‐AS1 and JHDM1D was observed. The downregulation of JHDM1D‐AS1 and SBF2‐AS1 , along with the upregulation of RP11‐363E7.4 , may be associated with the observed inhibition of proliferation and cell migration following bLAP treatment. The antiproliferative effects of bLAP in bladder cancer cells are independent of TP53 statuses, yet occur through a distinct action mechanism, with variations in lncRNAs expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal University of Ouro Preto, Ouro Preto, Brazil.
- Laboratory of Pain and Signaling, Butantan Institute, São Paulo, Brazil.
ORCID-Profile: Tatiane Roquete Amparo, Glenda Nicioli da Silva, Geraldo Célio Brandão
Zitieren
APA
Amparo, T. R., Anunciação, K. F. D., Almeida, T. C., Silva, G. N. D., & Brandão, G. C. (2025). Beta‐Lapachone: Effects on Proliferation, Survival, Migration, Cell Cycle, and lncRNA Modulation in Bladder Cancer Cells With Distinct TP53 Profiles. Drug Development Research. https://doi.org/10.1002/ddr.70128
Vancouver
Amparo TR, Anunciação KFD, Almeida TC, Silva GND, Brandão GC. Beta‐Lapachone: Effects on Proliferation, Survival, Migration, Cell Cycle, and lncRNA Modulation in Bladder Cancer Cells With Distinct TP53 Profiles. Drug Development Research. 2025. doi:10.1002/ddr.70128
BibTeX
@article{Amparo2025,
author = {Amparo, Tatiane Roquete and Anunciação, Kamila de Fátima da and Almeida, Tamires Cunha and Silva, Glenda Nicioli da and Brandão, Geraldo Célio},
title = {Beta‐Lapachone: Effects on Proliferation, Survival, Migration, Cell Cycle, and lncRNA Modulation in Bladder Cancer Cells With Distinct TP53 Profiles},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70128}
}
EUVIMED